JUL 10, 2018 10:30 PM PDT

The ALFRED Analysis for Cancer Predisposition Genes

A group of researchers in Spain methodically evaluated exome data from 10,000 tumors in an attempt to identify cancer predisposition genes as well as verify their statistical method.  They created a statistical method called ALFRED, which stands for allelic loss featuring rare damaging.  They used this method to evaluate Alfred Knudson’s classic “two hit” postulation which originated in 1971.  The article was published July 4, 2018 in Nature Communications.

Knudson was a geneticist researching retinoblastoma and his interest focused on the loss of function mechanism based on the knowledge that most tumor suppressor genes are recessive in nature.  This is what led him to propose the “two hit” hypothesis as a mechanism for the de novo development of cancer. 

The ALFRED model utilizes a principal component analysis to cluster common variants in cancer patients.  Then using two different test types, they quantify rare damaging germline variants with loss of heterozygosity events (termed allelic imbalance) compared to matched non-tumor samples from each patient which leads to an ALFRED P-value.  ALFRED was applied to 10,043 tumor exomes which had sequencing data as part of The Cancer Genome Atlas project. 

After evaluating the data against previously known cancer predisposition genes from recent literature reviews and the Cancer Gene Census, the group determined that these showed increased numbers of rare damaging germline variants with high frequency of allelic imbalance.  They also evaluated somatic cancer genes for germline risk variants; their findings indicate that there are a few genes that are affected by somatic changes but may also further cancer development because of rare germline variations.

The research points to potential new germline cancer predisposition variants including NSD1, MYH1, NOP56, PRPF8, INO80, ANK2, and ATM.

More significant research is needed to explore the use of a statistical method like ALFRED to further classify these cancer predisposition genes, in addition to clinical tumor testing research to identify these genes in patients with specific cancers.

Sources: Nature Communications, Nature Education, The Cancer Genome Atlas,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
MAY 29, 2018
Genetics & Genomics
MAY 29, 2018
A Pair of Genomes is Best
Researchers have now learned more about why cells that have improper numbers of chromosomes, which will help cancer research....
JUL 17, 2018
Cancer
JUL 17, 2018
Immunotherapy Diversification: From CAR-T cells to CAR-NK cells
New advances have made it possible for immunotherapy researchers to use natural killer cells, which are our body's normal defense for cancerous cells, to target tumors....
JUL 12, 2018
Infographics
JUL 12, 2018
3D Imaging Advantage
Learn about the advantages and the technology behind 3D cellular image acquisition and analysis with this infographic from Molecular Devices....
JUL 24, 2018
Cancer
JUL 24, 2018
Veterans with Cancer Get Streamlined Access to NCI Clinical Trials
Veterans with cancer, and the VA that cares for them, struggle to navigate the complex world of clinical trials but a collaborative agreement between VA and NCI could fix that....
AUG 26, 2018
Cancer
AUG 26, 2018
Can antireflux surgery prevent Esophageal cancer?
Heartburn or gastroesophageal reflux disease (GERD) is a widespread health problem affecting 10 to 20% of adults in Western populations. If GERD left untre...
SEP 13, 2018
Cancer
SEP 13, 2018
Breast tumors can stop their own metastasis
According to the American cancer society, metastatic breast cancers or stage 4 breast cancers have 5-years survival rate of 22% which is lower than at early stages. Metastatic breast cancer...
Loading Comments...